DIFFERENT EXPRESSION OF BRCA1 STATUS AND CLINICAL VARIABLES IN A SAMPLE OF ITALIAN WOMEN WITH EARLY ONSET BREAST CANCER (EOBC)
2004-01-01 Bella, Ma; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Capelletti, M; Neri, Tm; Savi, M; Bandini, N; Franciosi, V; De Lisi, V; Sgargi, P; Ardizzoni, A; Cascinu, S
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC)
2004-01-01 Bella, Ma; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Capelletti, M; Bandini, N; Franciosi, V
BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC)
2005-01-01 Bella, Ma; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Cappelletti, M; Neri, Tm; Savi, M; Bandini, N; De Lisi, V; Sgargi, P; Ardizzoni, A
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer
2006-01-01 Musolino, A; Naldi, N; Bortesi, B; Capelletti, M; Pezzuolo, D; Franciosi, D; Missale, G; Laccabue, D; Camisa, R; Ardizzoni, A
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC)
2016-01-01 Duchnowska, Renata; Jarzab, Michal; Zebracka, Jadwiga; Matkowski, Rafal; Kowalczyk, Anna; Radecka, Barbara; Foszczynska-Kloda, Malgorzata; Musolino, Antonino; Czartoryska-Arlukowicz, Bogumila; Litwiniuk, Maria Malgorzata; Szablowska-Siwik, Sylwia; Karczmarek-Borowska, Bozenna; Sosinska-Mielcarek, Katarzyna; Chmielowska, Ewa; Olszewski, Wojciech P; Patera, Janusz; Zawrocki, Anton; Rusinek, Dagmara; Jassem, Jacek; Biernat, Wojciech
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study
2016-01-01 Musolino, A; Sikokis, A; Boggiani, D; Rimanti, A; Pellegrino, B; Silini, Em; Campanini, N; Barbieri, E; Cortesi, L; Panebianco, M; Porzio, R; Frassoldati, A; Sgargi, P; Falcini, F; Michiara, M
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors
2017-01-01 Migliari, S; Sammartano, A; Pellegrino, B; Regina, V; Cavazzini, D; Ottonello, S; Missale, G; Musolino, A; Ruffini, L
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
2017-01-01 Conte, Pier Franco; Bisagni, Giancarlo; Frassoldati, Antonio; Brandes, Alba Ariela; Anselmi, Elisa; Giotta, Francesco; Aieta, Michele; Gebbia, Vittorio; Musolino, Antonino; Garrone, Ornella; Taverniti, Cristiana; Cavazzini, Giovanna; Turletti, Anna; Rubino, Daniela; Picardo, Elisa; Ferro, Antonella; Piacentini, Federico; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
2017-01-01 Musolino, Antonino; Porzio, Rosa; Rubino, Daniela; Frassoldati, Antonio; Caldara, Alessia; Schirone, Alessio; Gori, Stefania; Piacentini, Federico; Berardi, Rossana; Brandes, Alba Ariela; Cavazzini, Giovanna; Foglietta, Jennifer; Villa, Federica; Pellegrino, Benedetta; Camisa, Roberta; Todeschini, Renata; Tognetto, Michele; Naldi, Nadia; Baldari, Daniela; Montemurro, Filippo
Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
2017-01-01 Conte, P.; Conte, P.; Bisagni, G.; Frassoldati, A.; Brandes, A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Musolino, A.; Garrone, O.; Donadio, M.; Cavazzini, G.; Turletti, A.; Zamagni, C.; Danese, S.; Ferro, A.; Piacentini, F.; Balduzzi, S.; D'Amico, R.; Guarneri, V.
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
2018-01-01 Musolino, A; Gori, S; Cavanna, L; Graiff, C; Frassoldati, A; Bria, E; Bisagni, G; Zambelli, A; Partesotti, G; Brandes, A; Bonetti, A; Moscetti, L; Zamagni, C; Rocca, A; Generali, D; Montemurro, F; Gianni, L; Tognetto, M; Maglietta, G; Todeschini, R
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
2018-01-01 Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R.
Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
2018-01-01 Dieci, M. V.; Conte, P. F.; Bisagni, G.; Brandes, A. A.; Frassoldati, A.; Cavanna, L.; Musolino, A.; Giotta, F.; Rimanti, A.; Garrone, O.; Bertone, E.; Cagossi, K.; Sarti, S.; Ferro, A.; Omarini, C.; Maiorana, A.; Orvieto, E.; Sanders, M.; D'Amico, R.; Guarneri, V.
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
2019-01-01 Musolino, A; Cavanna, L; Boggiani, D; Zamagni, C; Frassoldati, A; Caldara, A; Rocca, A; Gori, S; Piacentini, F; Berardi, R; Brandes, Aa; Foglietta, J; Villa, F; Pellegrino, B; Todeschini, R; Tognetto, M; Naldi, N; Bortesi, B; Boni, L; Montemurro, F; Ardizzoni, A
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)
2019-01-01 Rugo, Hope S.; Im, Seock-Ah; Wright, Gail Lynn Shaw; Escriva-de-Romani, Santiago; Delaurentiis, Michelino; Cortes, Javier; Bahadur, Shakeela Wazeen; Haley, Barbara B.; Oyola, Raul H.; Riseberg, David A.; Musolino, Antonino; Cardoso, Fatima; Curigliano, Giuseppe; Kaufman, Peter A.; Pegram, Mark D.; Edlich, Sutton; Hong, Sam; Rock, Edwin P.; Gradishar, William John
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial
2019-01-01 Conte, Pier Franco; Griguolo, Gaia; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba Ariela; Frassoldati, Antonio; Cavanna, Luigi; Musolino, Antonino; Giotta, Francesco; Rimanti, Anita; Garrone, Ornella; Galvan, Patricia; Brasó Maristany, Fara; Orvieto, Enrico; Urso, Loredana; Maiorana, Antonino; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina; Prat, Aleix
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
2019-01-01 Pellegrino, B.; Llop-Guevara, A.; Pedretti, F.; Cruz, C.; Castroviejo, M.; Cedro-Tanda, A.; Fasani, R.; Mateo, F.; Musolino, A.; Pujana, M. A.; Nuciforo, P. G.; Gros, A.; Balmana, J.; O’Connor, M. J.; Serra Elizalde, V.
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy
2007-01-01 Negri, F.; Musolino, A.; Naldi, N.; Bortesi, B.; Boni, C.; Bisagni, G.; Camisa, R.; Ardizzoni, A.
HER2/NEU AMPLIFICATION IN FINE NEEDLE ASPIRATES FROM PRIMARY BREAST CANCER: IS IT A PREDICTIVE MARKER IN PATIENTS TREATED WITH NEOADJUVANT ANTHRACYCLINE BASED CHEMOTHERAPY?
2004-01-01 Bozzetti, ; C, (Bozzetti; Cecilia), ; Musolino, A; Personeni, ; N, (Personeni; Nicola);, Nizzoli; R, (Nizzoli; Rita);, Michiara; M, (Michiara; Maria); Di, Blasio; B (Di, Blasio; Beatrice);, Ceci; G, (Ceci; Guido);, Camisa; R, (Camisa; Roberta);, Cascinu; S, (Cascinu; Stefano);, Ardizzoni; A, (Ardizzoni; Andrea),
Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
2010-01-01 Musolino, A; Bisagni, ; G, (Bisagni; G., ); De Matteis; A (De, Matteis; A., ); Nuzzo; F, (Nuzzo; F., ); Ardizzoni; A, (Ardizzoni; A., ); Crino; L, (Crino; L., ); Gamucci; T, (Gamucci; T., ); Passalacqua; R, (Passalacqua; R., ); Gnoni; R, (Gnoni; R., ); Boni; C, (Boni; C., ).
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| DIFFERENT EXPRESSION OF BRCA1 STATUS AND CLINICAL VARIABLES IN A SAMPLE OF ITALIAN WOMEN WITH EARLY ONSET BREAST CANCER (EOBC) | 1-gen-2004 | Bella, Ma; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Capelletti, M; Neri, Tm; Savi, M; Bandini, N; Franciosi, V; De Lisi, V; Sgargi, P; Ardizzoni, A; Cascinu, S | |
| Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC) | 1-gen-2004 | Bella, Ma; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Capelletti, M; Bandini, N; Franciosi, V | |
| BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC) | 1-gen-2005 | Bella, Ma; Michiara, M; Musolino, A; Naldi, N; Zanelli, P; Bortesi, B; Cappelletti, M; Neri, Tm; Savi, M; Bandini, N; De Lisi, V; Sgargi, P; Ardizzoni, A | |
| Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer | 1-gen-2006 | Musolino, A; Naldi, N; Bortesi, B; Capelletti, M; Pezzuolo, D; Franciosi, D; Missale, G; Laccabue, D; Camisa, R; Ardizzoni, A | |
| Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) | 1-gen-2016 | Duchnowska, Renata; Jarzab, Michal; Zebracka, Jadwiga; Matkowski, Rafal; Kowalczyk, Anna; Radecka, Barbara; Foszczynska-Kloda, Malgorzata; Musolino, Antonino; Czartoryska-Arlukowicz, Bogumila; Litwiniuk, Maria Malgorzata; Szablowska-Siwik, Sylwia; Karczmarek-Borowska, Bozenna; Sosinska-Mielcarek, Katarzyna; Chmielowska, Ewa; Olszewski, Wojciech P; Patera, Janusz; Zawrocki, Anton; Rusinek, Dagmara; Jassem, Jacek; Biernat, Wojciech | |
| Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study | 1-gen-2016 | Musolino, A; Sikokis, A; Boggiani, D; Rimanti, A; Pellegrino, B; Silini, Em; Campanini, N; Barbieri, E; Cortesi, L; Panebianco, M; Porzio, R; Frassoldati, A; Sgargi, P; Falcini, F; Michiara, M | |
| [68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors | 1-gen-2017 | Migliari, S; Sammartano, A; Pellegrino, B; Regina, V; Cavazzini, D; Ottonello, S; Missale, G; Musolino, A; Ruffini, L | |
| 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER | 1-gen-2017 | Conte, Pier Franco; Bisagni, Giancarlo; Frassoldati, Antonio; Brandes, Alba Ariela; Anselmi, Elisa; Giotta, Francesco; Aieta, Michele; Gebbia, Vittorio; Musolino, Antonino; Garrone, Ornella; Taverniti, Cristiana; Cavazzini, Giovanna; Turletti, Anna; Rubino, Daniela; Picardo, Elisa; Ferro, Antonella; Piacentini, Federico; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina | |
| Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) | 1-gen-2017 | Musolino, Antonino; Porzio, Rosa; Rubino, Daniela; Frassoldati, Antonio; Caldara, Alessia; Schirone, Alessio; Gori, Stefania; Piacentini, Federico; Berardi, Rossana; Brandes, Alba Ariela; Cavazzini, Giovanna; Foglietta, Jennifer; Villa, Federica; Pellegrino, Benedetta; Camisa, Roberta; Todeschini, Renata; Tognetto, Michele; Naldi, Nadia; Baldari, Daniela; Montemurro, Filippo | |
| Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer | 1-gen-2017 | Conte, P.; Conte, P.; Bisagni, G.; Frassoldati, A.; Brandes, A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Musolino, A.; Garrone, O.; Donadio, M.; Cavazzini, G.; Turletti, A.; Zamagni, C.; Danese, S.; Ferro, A.; Piacentini, F.; Balduzzi, S.; D'Amico, R.; Guarneri, V. | |
| Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) | 1-gen-2018 | Musolino, A; Gori, S; Cavanna, L; Graiff, C; Frassoldati, A; Bria, E; Bisagni, G; Zambelli, A; Partesotti, G; Brandes, A; Bonetti, A; Moscetti, L; Zamagni, C; Rocca, A; Generali, D; Montemurro, F; Gianni, L; Tognetto, M; Maglietta, G; Todeschini, R | |
| 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio | 1-gen-2018 | Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R. | |
| Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial | 1-gen-2018 | Dieci, M. V.; Conte, P. F.; Bisagni, G.; Brandes, A. A.; Frassoldati, A.; Cavanna, L.; Musolino, A.; Giotta, F.; Rimanti, A.; Garrone, O.; Bertone, E.; Cagossi, K.; Sarti, S.; Ferro, A.; Omarini, C.; Maiorana, A.; Orvieto, E.; Sanders, M.; D'Amico, R.; Guarneri, V. | |
| Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) | 1-gen-2019 | Musolino, A; Cavanna, L; Boggiani, D; Zamagni, C; Frassoldati, A; Caldara, A; Rocca, A; Gori, S; Piacentini, F; Berardi, R; Brandes, Aa; Foglietta, J; Villa, F; Pellegrino, B; Todeschini, R; Tognetto, M; Naldi, N; Bortesi, B; Boni, L; Montemurro, F; Ardizzoni, A | |
| SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) | 1-gen-2019 | Rugo, Hope S.; Im, Seock-Ah; Wright, Gail Lynn Shaw; Escriva-de-Romani, Santiago; Delaurentiis, Michelino; Cortes, Javier; Bahadur, Shakeela Wazeen; Haley, Barbara B.; Oyola, Raul H.; Riseberg, David A.; Musolino, Antonino; Cardoso, Fatima; Curigliano, Giuseppe; Kaufman, Peter A.; Pegram, Mark D.; Edlich, Sutton; Hong, Sam; Rock, Edwin P.; Gradishar, William John | |
| PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial | 1-gen-2019 | Conte, Pier Franco; Griguolo, Gaia; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba Ariela; Frassoldati, Antonio; Cavanna, Luigi; Musolino, Antonino; Giotta, Francesco; Rimanti, Anita; Garrone, Ornella; Galvan, Patricia; Brasó Maristany, Fara; Orvieto, Enrico; Urso, Loredana; Maiorana, Antonino; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina; Prat, Aleix | |
| PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors | 1-gen-2019 | Pellegrino, B.; Llop-Guevara, A.; Pedretti, F.; Cruz, C.; Castroviejo, M.; Cedro-Tanda, A.; Fasani, R.; Mateo, F.; Musolino, A.; Pujana, M. A.; Nuciforo, P. G.; Gros, A.; Balmana, J.; O’Connor, M. J.; Serra Elizalde, V. | |
| 522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy | 1-gen-2007 | Negri, F.; Musolino, A.; Naldi, N.; Bortesi, B.; Boni, C.; Bisagni, G.; Camisa, R.; Ardizzoni, A. | |
| HER2/NEU AMPLIFICATION IN FINE NEEDLE ASPIRATES FROM PRIMARY BREAST CANCER: IS IT A PREDICTIVE MARKER IN PATIENTS TREATED WITH NEOADJUVANT ANTHRACYCLINE BASED CHEMOTHERAPY? | 1-gen-2004 | Bozzetti, ; C, (Bozzetti; Cecilia), ; Musolino, A; Personeni, ; N, (Personeni; Nicola);, Nizzoli; R, (Nizzoli; Rita);, Michiara; M, (Michiara; Maria); Di, Blasio; B (Di, Blasio; Beatrice);, Ceci; G, (Ceci; Guido);, Camisa; R, (Camisa; Roberta);, Cascinu; S, (Cascinu; Stefano);, Ardizzoni; A, (Ardizzoni; Andrea), | |
| Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer | 1-gen-2010 | Musolino, A; Bisagni, ; G, (Bisagni; G., ); De Matteis; A (De, Matteis; A., ); Nuzzo; F, (Nuzzo; F., ); Ardizzoni; A, (Ardizzoni; A., ); Crino; L, (Crino; L., ); Gamucci; T, (Gamucci; T., ); Passalacqua; R, (Passalacqua; R., ); Gnoni; R, (Gnoni; R., ); Boni; C, (Boni; C., ). |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Articolo su rivista1819
Data di pubblicazione
- 2020 - 2026208
- 2010 - 2019847
- 2000 - 2009537
- 1990 - 1999175
- 1980 - 198951
- 1979 - 19791
Editore
- ELSEVIER25
- Elsevier17
- SAGE PUBLICATIONS LTD17
- DIKE GIURIDICA15
- ASCO pubs11
- ELSEVIER IRELAND LTD7
- ASCO6
- ELSEVIER SCIENCE INC5
- SAGE5
- SPRINGERNATURE4
Rivista
- DIGESTIVE AND LIVER DISEASE101
- GASTROENTEROLOGY100
- ANNALS OF ONCOLOGY94
- BLOOD91
- HAEMATOLOGICA59
- JOURNAL OF CLINICAL ONCOLOGY58
- NEUROLOGICAL SCIENCES47
- UNITED EUROPEAN GASTROENTEROLOGY ...46
- ANNALS OF THE RHEUMATIC DISEASES36
- EPILEPSIA26
Keyword
- Helicobacter pylori10
- epilepsy9
- sclerosi sistemica6
- Bioengineering5
- Gastroenterology5
- HCV5
- temporal lobe epilepsy5
- UV5
- GERD4
- Lungs4
Lingua
- eng969
- ita176
- fre1
Accesso al fulltext
- no fulltext1787
- reserved26
- open6